Image by Adeolu Eletu

PRESS RELEASE

Development of Stem Cell Therapies for Aging-related Conditions

 

June 21, 2018

 

Dr. Joshua Hare, MD, co-founder and Chief Science Officer of biotech company Longeveron, and founding director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine, discusses two published positive clinical studies of stem cell treatment for aging frailty and how Longeveron is progressing with development of stem cell therapies for aging-related conditions to improve quality of life. www.longeveron.com

 

Dr. Joshua Hare co-founded Longeveron in 2014 utilizing intellectual property and technology exclusively licensed from the University of Miami, where he is also the founding Director of the university’s Interdisciplinary Stem Cell Institute (ISCI). At the University of Miami Miller School of Medicine, he is chief of the Division of Cardiology, and Louis Lemberg professor of medicine and professor of molecular and cellular pharmacology. Dr. Hare graduated from the University of Pennsylvania and has a medical degree from Johns Hopkins University. He did his residency at Hopkins and fellowships at Hopkins, Harvard University and The Brigham and Women’s Hospital in Boston. Dr. Hare was Professor of Medicine and Biomedical Engineering and director of cardiac transplantation at Johns Hopkins, prior to joining the faculty at University of Miami.

 

About Longeveron 

 

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014.  Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life.  The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund.  Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.

 

For more information about the clinical trials

Longeveron is sponsoring, visit ClinicalTrials.gov

or Longeveron’s website www.longeveron.com

 

SOURCE Longeveron LLC

 

Related Links

www.longeveron.com

________

  • Facebook
  • Twitter
  • LinkedIn

________________

_________

________

__________

_____________

_________

© Copyright 2021 Longeveron. All rights reserved.